Chronic Methylphenidate Effects on Brain Gene Expression: An Exploratory Review
Shannon Klein,Kenneth Blum,Mark Gold,Panayotis Thanos
DOI: https://doi.org/10.2147/prbm.s445719
IF: 3.974
2024-02-15
Psychology Research and Behavior Management
Abstract:Shannon Rae Klein, 1 Kenneth Blum, 2 Mark S Gold, 3 Panayotis K Thanos 1, 4 1 Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions (BNNLA), Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA; 2 Center for Sports, Exercise, & Mental Health, Western University Health Sciences, Pomona, CA, 91766, USA; 3 Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, 63130, USA; 4 Department of Psychology, University at Buffalo, Buffalo, NY, 14203, USA Correspondence: Panayotis K Thanos, Tel +1 716 881-7520, Email Methylphenidate (MP) is a psychostimulant commonly prescribed for individuals with attention deficit hyperactivity disorder (ADHD) but it is also taken with and without a prescription for performance enhancement. Prior research has characterized the effects of MP on behavior, cognition, and neurochemistry. This exploratory review covers the uses of MP and examined the effects of MP on gene expression in the brain following exposure. Overall, MP causes a wide-spread potentiation of genes, in a region-specific manner; consequently, inducing neuronal alterations, such as synaptic plasticity and transmission, resulting in observed behaviors and affects. Monoamine neurotransmitters and post-synaptic density protein genes generally had a potentiating effect in gene expression after exposure to MP. Keywords: addiction, substance abuse, methylphenidate, gene expression, monoamine neurotransmitters postsynaptic density proteins, reward deficiency syndrome Methylphenidate (MP), also marketed as Ritalin ® , is the treatment of choice of attention deficit hyperactivity disorder (ADHD). MP was first synthesized in 1944, then subsequently patented in 1954; however, it was not until 2002 when the FDA approved it for the treatment of both ADHD and narcolepsy. 1 ADHD . MP is prescribed for individuals diagnosed with ADHD, which is a neurobehavioral disorder associated with lack of attention, hyperactivity, and impulsivity, according to the National Institute of Mental Health. 2–6 While it is an important prescription medication for ADHD, it is also misused, abused, prescribed off-label, and taken for performance enhancement. 7 According to the CDC, it is estimated that, as of 2016, 6.1 million children in the US were diagnosed with ADHD, which is 9.4% of all children. 8 One study used functional magnetic resonance imaging (fMRI) to isolate the regions of activity in the brains of individuals with ADHD, through neurophysiological tests. 9 Results showed an increase in activity, specifically in the frontostriatal regions of the brain. 9 The frontostriatal regions of the brain are the areas of the brain associated with inhibitory control, including motor, limbic, and cognitive control, along with attention and focus control. 6,10 ADHD can be diagnosed from childhood to adulthood; yet diagnosis in adults is more closely accessed to limit abuse. 9 Continually, ADHD patients using MP may experience adverse side-effects, although usually well tolerated. These include, but are not limited to, insomnia, nervousness, anorexia, and cardiovascular complications such as hypertension. 11 Narcolepsy. Narcolepsy is a neurological sleep disorder affecting about 0.05% of people, generally with onset before the age of 25 in the US. 12 Narcolepsy is characterized by excessive sleepiness, "...irresistible sleep attacks, cataplexy (sudden bilateral loss of muscle tone), hypnagogic hallucination, and sleep paralysis". 6,13 There are two types, type one and two narcolepsy, (Na-1) and (Na-2), respectively. 12 Moreover, it has been found that MP has improved the conditions for individuals living with narcolepsy. 14 Overall, MP, through its effects on catecholamine release, results in changes in heart rate and constriction and improvements in REM sleep in narcolepsy patients. 15 MP non-prescribed and misuse. MP is considered a narcotic, recognized as a class II controlled substance and, thus, has a high potential for individuals developing physical dependence. 16 Previous studies have indicated that MP is a relatively safe treatment when taken within intended use and prescription. However, one study included that 8.9% of participants of a national US surveyadmitted to having a MP prescription. 17 Moreover, MP is abused specifically for its cognitive effects rather than its intended use. And, in terms of unsolicited use, chronic safety has not y -Abstract Truncated-
psychology, clinical, multidisciplinary